Go To Global Site
Welcome to UCB in the United States

Mar

28

Press Release: CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis

  • Patients living with non-radiographic axial spondyloarthritis, an often undiagnosed, chronic, painful and debilitating disease, now have an approved, clinically validated treatment
  • FDA approval was based on the C-AXSPAND Phase 3 study in adults with non-radiographic axial spondyloarthritis, which demonstrated rapid and major improvement response with CIMZIA compared to placebo. Patients remained on common background medications, which could be adjusted at any point during the study

Mar

20

Championing STEM Education for Tomorrow’s Discoveries

At UCB, we are inspired by patients and driven by science to deliver what patients value. We are committed to continuously working to advance science and embrace new knowledge — leading to the discovery of new solutions that help patients achieve their goals.

Mar

13

Driving Our Patient Value Strategy for the Future

2018 marked the 90th anniversary of UCB. Since our creation in 1928, UCB has been characterized by a strong entrepreneurial spirit, determination and resilience, long term views, and a strong belief science and innovation would improve humanity.

Mar

11

Press Release: Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)

Mar

06

Press Release: UCB Ventures Appoints Alicia Irurzun-Lafitte as Partner

Mar

02

Press Release: Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

Mar

01

Press Release: New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio